{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:24:10Z","timestamp":1783607050344,"version":"3.55.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1197951"],"award-info":[{"award-number":["APP1197951"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The LightMix\u00ae Modular Mycoplasma Macrolide and LightMix\u00ae Modular parC Fluoroquinolone Resistance assays (TIB Molbiol) were evaluated using sequential Mycoplasma genitalium positive (n\u00a0=\u00a0125) and negative (n\u00a0=\u00a093) clinical samples. Results were compared to the results of an established commercial assay (ResistancePlus MG assay, SpeeDx Pty Ltd) or Sanger sequencing (for parC). Detection of M. genitalium by the TIB Molbiol assay had a high agreement with the reference assay, with a positive percent agreement (PPA) of 97.6 [95% confidence interval (CI): 93.1\u201399.5] and negative percent agreement (NPA) of 95.7 (95% CI: 89.5\u201398.8). From 105 positive samples, macrolide resistance detection had a PPA of 100% (95% CI: 93.7\u2013100) and NPA of 81.3% (95% CI: 67.4\u201391.1). For the detection of fluroquinolone resistance mutation G248T\/S83I or \u201cother mutation\u201d in the quinolone resistance determinant region, from 95 samples there was 100% (95% CI: 86.3\u2013100) sensitivity and 100% (95% CI: 94.5\u2013100) specificity. The understanding of the basis for fluoroquinolone treatment failure is still developing; it is therefore important to use the output of parC-based resistance assays with caution to avoid the inappropriate use of antibiotic therapies, especially considering the limited number of alternative treatments.<\/jats:p>","DOI":"10.1093\/lambio\/ovad124","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T07:23:32Z","timestamp":1698305012000},"source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of TIB Molbiol LightMix\u00ae assays for detection of <i>Mycoplasma genitalium<\/i> and key resistance mutations for macrolides and fluoroquinolones"],"prefix":"10.1093","volume":"76","author":[{"given":"Prisha","family":"Balgovind","sequence":"first","affiliation":[{"name":"Centre for Women\u2019s Infectious Diseases, The Royal Women\u2019s Hospital , Parkville, VIC 3052 , Australia"},{"name":"Molecular Microbiology Research Group, Murdoch Children\u2019s Research Institute , Parkville, VIC 3052 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steph","family":"Atchison","sequence":"additional","affiliation":[{"name":"Centre for Women\u2019s Infectious Diseases, The Royal Women\u2019s Hospital , Parkville, VIC 3052 , Australia"},{"name":"Molecular Microbiology Research Group, Murdoch Children\u2019s Research Institute , Parkville, VIC 3052 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Danielewski","sequence":"additional","affiliation":[{"name":"Centre for Women\u2019s Infectious Diseases, The Royal Women\u2019s Hospital , Parkville, VIC 3052 , Australia"},{"name":"Molecular Microbiology Research Group, Murdoch Children\u2019s Research Institute , Parkville, VIC 3052 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M","family":"Garland","sequence":"additional","affiliation":[{"name":"Centre for Women\u2019s Infectious Diseases, The Royal Women\u2019s Hospital , Parkville, VIC 3052 , Australia"},{"name":"Molecular Microbiology Research Group, Murdoch Children\u2019s Research Institute , Parkville, VIC 3052 , Australia"},{"name":"Department of Obstetrics and Gynaecology, University of Melbourne , Parkville, VIC 3052 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Costa","sequence":"additional","affiliation":[{"name":"Centre for Women\u2019s Infectious Diseases, The Royal Women\u2019s Hospital , Parkville, VIC 3052 , Australia"},{"name":"The Royal Children\u2019s Hospital , Parkville, VIC 3052 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveesha","family":"Bodiyabadu","sequence":"additional","affiliation":[{"name":"Centre for Women\u2019s Infectious Diseases, The Royal Women\u2019s Hospital , Parkville, VIC 3052 , Australia"},{"name":"Molecular Microbiology Research Group, Murdoch Children\u2019s Research Institute , Parkville, VIC 3052 , Australia"},{"name":"Department of Obstetrics and Gynaecology, University of Melbourne , Parkville, VIC 3052 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3330-4433","authenticated-orcid":false,"given":"Gerald L","family":"Murray","sequence":"additional","affiliation":[{"name":"Centre for Women\u2019s Infectious Diseases, The Royal Women\u2019s Hospital , Parkville, VIC 3052 , Australia"},{"name":"Molecular Microbiology Research Group, Murdoch Children\u2019s Research Institute , Parkville, VIC 3052 , Australia"},{"name":"Department of Obstetrics and Gynaecology, University of Melbourne , Parkville, VIC 3052 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"2023110900110162500_bib1","article-title":"Mycoplasma genitalium\u2014Australian STI Management Guidelines for use in Primary Care","author":"Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM)","year":"2022"},{"key":"2023110900110162500_bib2","doi-asserted-by":"crossref","first-page":"001257","DOI":"10.1099\/jmm.0.001257","article-title":"Detection of parC gene mutations associated with quinolone resistance in Mycoplasma genitalium: evaluation of a multiplex real-time PCR assay","volume":"70","author":"Bodiyabadu","year":"2021","journal-title":"J Med Microbiol"},{"key":"2023110900110162500_bib3","volume-title":"Sexually Transmitted Infections Treatment Guidelines, 2021","author":"Centers for Disease Control and Prevention (CDC)","year":"2021"},{"key":"2023110900110162500_bib4","first-page":"1550","article-title":"Point-of-care amenable detection of Mycoplasma genitalium and its antibiotic resistance mutations","volume-title":"ACS Sens","author":"Chen","year":"2023"},{"key":"2023110900110162500_bib5","doi-asserted-by":"crossref","first-page":"e0113522","DOI":"10.1128\/jcm.01135-22","article-title":"Clinical performance of three commercial molecular diagnostic assays for the detection of fluoroquinolone resistance-associated mutations in Mycoplasma genitalium","volume":"60","author":"Gardette","year":"2022","journal-title":"J Clin Microbiol"},{"key":"2023110900110162500_bib6","doi-asserted-by":"crossref","first-page":"S396","DOI":"10.1093\/infdis\/jix145","article-title":"Mycoplasma genitalium infection in Men","volume":"216","author":"Horner","year":"2017","journal-title":"J Infect Dis"},{"key":"2023110900110162500_bib7","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/jdv.17972","article-title":"2021 European guideline on the management of Mycoplasma genitalium infections","volume":"36","author":"Jensen","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023110900110162500_bib8","first-page":"277","article-title":"The clinical indications for testing women for Mycoplasma genitalium","volume":"98","author":"Latimer","year":"2022","journal-title":"Sex Transm Infect"},{"key":"2023110900110162500_bib9","first-page":"e0101422","article-title":"Rapid detection of antimicrobial resistance in Mycoplasma genitalium by high-resolution melting analysis with unlabeled probes","volume-title":"Microbiol Spectr","author":"Li","year":"2022"},{"key":"2023110900110162500_bib10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/cid\/civ312","article-title":"Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis","volume":"61","author":"Lis","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023110900110162500_bib11","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S1473-3099(20)30154-7","article-title":"Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis","volume":"20","author":"Machalek","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2023110900110162500_bib12","first-page":"1017","article-title":"Moxifloxacin and sitafloxacin treatment failure in Mycoplasma genitalium infection: association with parC mutation G248T (S83I) and concurrent gyrA mutations","volume":"221","author":"Murray","year":"2020","journal-title":"J Infect Dis"},{"key":"2023110900110162500_bib13","doi-asserted-by":"crossref","first-page":"e0027822","DOI":"10.1128\/aac.00278-22","article-title":"parC variants in Mycoplasma genitalium: trends over time and association with moxifloxacin failure","volume":"66","author":"Murray","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023110900110162500_bib14","doi-asserted-by":"crossref","first-page":"e00344","DOI":"10.1128\/JCM.00344-19","article-title":"Analysis of infection loads in Mycoplasma genitalium clinical specimens by use of a commercial diagnostic test","volume":"57","author":"Murray","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2023110900110162500_bib15","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/cid\/ciad057","article-title":"gyrA mutations in Mycoplasma genitalium and their contribution to moxifloxacin failure: time for the next generation of resistance-guided therapy","volume":"76","author":"Murray","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023110900110162500_bib16","doi-asserted-by":"crossref","first-page":"859732","DOI":"10.3389\/fmicb.2022.859732","article-title":"Genital mycoplasmas and biomarkers of inflammation and their association with spontaneous preterm birth and preterm prelabor rupture of membranes: a systematic review and meta-analysis","volume":"13","author":"Noda-Nicolau","year":"2022","journal-title":"Front Microbiol"},{"key":"2023110900110162500_bib17","doi-asserted-by":"crossref","first-page":"106089","DOI":"10.1016\/j.mimet.2020.106089","article-title":"A custom amplicon sequencing approach to detect resistance associated mutations and sequence types in Mycoplasma genitalium","volume":"179","author":"Plummer","year":"2020","journal-title":"J Microbiol Methods"},{"key":"2023110900110162500_bib18","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/cid\/ciy477","article-title":"Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation","volume":"68","author":"Read","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023110900110162500_bib19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3201\/eid2504.181258","article-title":"Symptoms, sites, and significance of Mycoplasma genitalium in men who have sex with men","volume":"25","author":"Read","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2023110900110162500_bib20","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s10096-021-04170-0","article-title":"Clinical evaluation of commercial PCR assays for antimicrobal resistance in Mycoplasma genitalium and estimation of resistance-mediated mutation prevalence in Moscow and Moscow region","volume":"40","author":"Shedko","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023110900110162500_bib21","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1177\/0956462419825948","article-title":"British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium (2018)","volume":"30","author":"Soni","year":"2019","journal-title":"Int J STD AIDS"},{"key":"2023110900110162500_bib22","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S1473-3099(21)00629-0","article-title":"Individualised treatment of Mycoplasma genitalium infection-incorporation of fluoroquinolone resistance testing into clinical care","volume":"22","author":"Sweeney","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2023110900110162500_bib23","doi-asserted-by":"crossref","first-page":"e01555","DOI":"10.1128\/JCM.01555-18","article-title":"Levels of Mycoplasma genitalium antimicrobial resistance differ by both region and gender in the state of Queensland, Australia: implications for treatment guidelines","volume":"57","author":"Sweeney","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2023110900110162500_bib24","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/jac\/dkac097","article-title":"Novel probe-based melting curve assays for the characterization of fluoroquinolone resistance in Mycoplasma genitalium","volume":"77","author":"Tickner","year":"2022","journal-title":"J Antimicrob Chemother"}],"container-title":["Letters in Applied Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/lambio\/advance-article-pdf\/doi\/10.1093\/lambio\/ovad124\/52556313\/ovad124.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/lambio\/article-pdf\/76\/11\/ovad124\/52935290\/ovad124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/lambio\/article-pdf\/76\/11\/ovad124\/52935290\/ovad124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:11:22Z","timestamp":1699488682000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/lambio\/article\/doi\/10.1093\/lambio\/ovad124\/7330186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/lambio\/ovad124","relation":{},"ISSN":["1472-765X"],"issn-type":[{"value":"1472-765X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,10,25]]},"article-number":"ovad124"}}